KRAS and lung adenocarcinoma: Foggetti et al. used a CRISPR-Cas9 based approach to screen the effects of select mutations on development of lung adenocarcinoma initiated by Egfr/Trp53 or Kras/Trp53 mutations (Foggetti et al., 2021).